8 assets in Bronchogenic Carcinoma

Therapeutic assets addressing Bronchogenic Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Bronchogenic Carcinoma	Nanfang Hospital, Southern Medical University	P3	BB (68)
Cis-Diamminedichloroplatinum Ii Bronchogenic Carcinoma	Nanfang Hospital, Southern Medical University	P3	BB (64)
Adebrelimab Bronchogenic Carcinoma	Nanfang Hospital, Southern Medical University	P2	CCC (53)
Atezolizumab Bronchogenic Carcinoma	Fundación GECP	P2	CCC (53)
Etoposide Bronchogenic Carcinoma	Nanfang Hospital, Southern Medical University	P2	CCC (53)
Blu-701 Bronchogenic Carcinoma	Blueprint Medicines Corporation	P1	CC (43)
Osimertinib Bronchogenic Carcinoma	Blueprint Medicines Corporation	P1	CC (43)
Pebezertinib Bronchogenic Carcinoma	Blueprint Medicines Corporation	P1	CC (43)